An interesting finding in our study was that treatment with vemurafenib and the combination of vemurafenib + tretinoin significantly increased expression of RAR-β, RAR-γ, RXR-α, and RXR-β and reduced expression of RAR-α and RXR-γ, which may promote responsiveness to tretinoin in these melanoma cells. The gene discussed is RARG; the disease is melanoma.